Innovent Biologics Receives Positive CHMP Opinion for Zybrivo in Europe
Innovent Biologics' Groundbreaking Step in Europe
On November 15, 2026, Innovent Biologics, Inc. announced a significant regulatory achievement as it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This endorsement recommends the marketing authorization of Zybrivo® (sintilimab) in combination with chemotherapy for the first-line treatment of adult patients suffering from advanced non-squamous non-small cell lung cancer (NSCLC).
The approval from the CHMP represents an important milestone for Innovent, potentially expanding the treatment landscape for lung cancer patients across Europe. If sanctioned by the European Commission, Zybrivo will offer an enhanced treatment option for eligible patients, addressing a critical need in lung cancer therapies. This development is particularly timely, considering lung cancer remains the leading cause of cancer-related deaths in the European Union, accounting for roughly one in five cancer deaths.
Clinical Trials Highlight Efficacy
The CHMP's positive opinion is founded on encouraging outcomes from the Phase 3 ORIENT-11 study (NCT03607539), a pivotal research trial that assessed the efficacy of sintilimab in combination with standard chemotherapy. The study involved 397 adult patients diagnosed with locally advanced or metastatic non-squamous NSCLC, all lacking EGFR or ALK genomic tumor aberrations.
In this trial, patients were randomly assigned to receive either sintilimab plus chemotherapy or a placebo plus chemotherapy. Results revealed that patients treated with sintilimab exhibited a remarkable 52% reduction in the risk of disease progression or death, achieving a median progression-free survival (PFS) of 8.9 months compared to just 5.0 months for the placebo group. Additionally, the overall survival (OS) rate significantly improved, with those receiving sintilimab experiencing a median OS of 24.2 months, compared to 16.8 months for the placebo cohort.
Safety Profile Consistent with Expectations
The safety profile of sintilimab when paired with chemotherapy aligned with the known safety expectations for PD-1 inhibitors and the chemotherapy agents used. Importantly, no new safety signals were identified during the study, underscoring the therapeutic potential and overall safety of sintilimab when used in this context.
As the European Commission mulls over the CHMP's recommendation, it is anticipated that a final decision on marketing authorization will be issued shortly. Approval would not only apply to the 27 member states of the European Union but also extend to Iceland, Norway, and Liechtenstein, thereby widening access to this promising treatment.
About Zybrivo and Sintilimab
Zybrivo, a human immunoglobulin G4 (IgG4) monoclonal antibody, operates by targeting the programmed cell death protein 1 (PD-1), an important mechanism that cancer cells employ to evade the host's immune response. By blocking PD-1’s interaction with its ligands PD-L1 and PD-L2, sintilimab can enhance the body's immune system to more effectively combat cancer cells.
Sintilimab is already approved in China for various oncology indications, including squamous and non-squamous NSCLC, and has already benefited approximately 3 million patients in the country. If approved in Europe, this treatment could mark a considerable shift in managing advanced lung cancer in this region.
Looking Ahead
Innovent’s commitment to developing high-quality biopharmaceuticals drives the company to expand its product portfolio to meet pressing healthcare needs globally. As the firm continues to advocate for affordable and effective therapies, the positive CHMP opinion signifies just one step in their broader mission. With more products under development and partnerships established with notable pharmaceutical companies, Innovent is poised to make significant contributions to patient care both in Europe and beyond.
In summary, the positive recommendation for Zybrivo represents a beacon of hope for patients battling advanced non-squamous non-small cell lung cancer, offering them another viable treatment option on their journey to recovery.